News & Events

• Sigmapharm launches its 7^th generic product, Liothyronine Sodium Tablets, USP 5 mcg, 25 mcg and 50 mcg, exclusively under its own label.  This is the company’s 1^st generic product marketed solely under Sigmapharm’s own label.


• Sigmapharm receives FDA approval for generic Liothyronine Sodium Tablets, USP 5 mcg, 25 mcg and 50 mcg, based on its ANDA No. 200295.   


• Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 6^th generic product, Utramicrosize Griseofulvin Tablets, USP 125 mg and 250 mg, which is the first-and-only approved generic equivalent to GRIS-PEG^® Tablets.

• Sigmapharm receives FDA approval for generic Griseofulvin Tablets, USP (microsize) 500 mg, based on its ANDA No. 202482.


• Sigmapharm receives FDA approval for generic Utramicrosize Griseofulvin Tablets, USP 125 mg and 250 mg, based on its ANDA No. 202545.

Sigmapharm files an Abbreviated New Drug Application (ANDA No. 204633).

Sigmapharm successfully completes an FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 202819.

Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 5^th generic product, Flucytosine Capsules, USP 250 mg and 500 mg, which is the first-and-only approved generic equivalent to ANCOBON^® Capsules.

Sigmapharm receives FDA approval for generic Flucytosine Capsules, USP 250 mg and 500 mg, based on its ANDA No. 201566.

Sigmapharm successfully completes an FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 202051.

Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 4^th generic product, Disulfiram Tablets, USP 250 mg, which is the first-and-only approved generic equivalent to ANTABUSE^® Tablets.

Sigmapharm receives FDA approval for generic Disulfiram Tablets, USP 250 mg and 500 mg, based on its ANDA No. 091619.

Sigmapharm files an Abbreviated New Drug Application (ANDA No. 202819).